A phase two randomised controlled double blind trial of high dose intravenous Methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment

PLoS Neglected Tropical Diseases

Volumn 5, Issue 4, 2011, Pages

  Walker, Stephen L ^a   Nicholls, Peter G ^b   Dhakal, Sushmita ^c   Hawksworth, Rachel A ^c   Macdonald, Murdo ^c   Mahat, Kishori ^c   Ruchal, Shudan ^c   Hamal, Sushma ^c   Hagge, Deanna A ^c   Neupane, Kapil D ^c   Lockwood, Diana N J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Anandaban Leprosy Hospital   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; PREDNISOLONE; SODIUM CHLORIDE; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLAUCOMA; HUMAN; HYPERTENSION; INFLAMMATION; LEPROSY TYPE 1 REACTION; MALE; MOON FACE; MYCOSIS; NEUROPATHY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; SIDE EFFECT; STOMACH PAIN; TREATMENT DURATION; TUBERCULOSIS; ULCER; WEIGHT GAIN; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; LEPROSY; MIDDLE AGED; PERIPHERAL NEUROPATHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LEPROSY; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PREDNISOLONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955810298     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001041     Document Type: Article

References (23)

1. Moher D, Schulz KF, Altman DG, (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357: 1191-1194.
2. Lockwood DNJ, (2004) Leprosy. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, editors. Rook's Textbook of Dermatology 7th ed Oxford Blackwell Publishing pp. 29.21-29.21.
3. WHO, (2009) Global leprosy situation, 2009. Wkly Epidemiol Rec 84: 333-340.
4. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, et al. (2007) Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44: 33-40.
5. Marlowe SN, Hawksworth RA, Butlin CR, Nicholls PG, Lockwood DN, (2004) Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg 98: 602-609.
6. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, et al. (2003) Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev 74: 311-318.
7. van Brakel WH, Anderson AM, Withington SG, Croft RP, Nicholls PG, et al. (2003) The prognostic importance of detecting mild sensory impairment in leprosy: a randomized controlled trial (TRIPOD 2). Lepr Rev 74: 300-310.
8. Little D, Khanolkar-Young S, Coulthart A, Suneetha S, Lockwood DN, (2001) Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment. Infect Immun 69: 3413-3417.
9. Khanolkar-Young S, Rayment N, Brickell PM, Katz DR, Vinayakumar S, et al. (1995) Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions. Clin Exp Immunol 99: 196-202.
10. Weusten BL, Jacobs JW, Bijlsma JW, (1993) Corticosteroid pulse therapy in active rheumatoid arthritis. Semin Arthritis Rheum 23: 183-192.
11. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, et al. (2000) Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev pp. CD001331.
12. Wandinger KP, Wessel K, Trillenberg P, Heindl N, Kirchner H, (1998) Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. Acta Neurol Scand 97: 359-365.
13. Youssef PP, Haynes DR, Triantafillou S, Parker A, Gamble JR, et al. (1997) Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum 40: 1400-1408.
14. Hirano T, Tsuboi N, Homma M, Oka K, Takekoshi T, et al. (2000) Comparative study of lymphocyte-suppressive potency between prednisolone and methylprednisolone in rheumatoid arthritis. Immunopharmacology 49: 411-417.
15. Ridley DS, Jopling WH, (1966) Classification of Leprosy according to immunity. Int J Lepr Other Mycobact Dis 34: 255-273.
16. Richardus JH, Withington SG, Anderson AM, Croft RP, Nicholls PG, et al. (2003) Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials. Lepr Rev 74: 319-327.
17. Walker SL, Nicholls PG, Butlin CR, Nery JA, Roy HK, et al. (2008) Development and validation of a severity scale for leprosy type 1 reactions. PLoS Negl Trop Dis 2: e351.
18. Brain, (2000) Aids to the examination of the peripheral nervous system. Philadelphia W.B. Saunders.
19. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, et al. (2006) Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 74: 868-879.
20. Smith WC, Anderson AM, Withington SG, van Brakel WH, Croft RP, et al. (2004) Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 328: 1459.
21. Rao PS, Sugamaran DS, Richard J, Smith WC, (2006) Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 77: 25-33.
22. Walker SL, Lockwood DN, (2008) Leprosy type 1 (reversal) reactions and their management. Lepr Rev 79: 372-386.
23. Naafs B, (2003) Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr Rev 74: 328-336.